xylometazoline | Snoop spray nasal 0.05%, 15 ml of pfs 0.164, 1 ml pfsfrod 0.164 pf30fsf4 pf30 dsfap 0.15 %, 15 ml
Special Price
$15.52
Regular Price
$23.00
In stock
SKU
BID464186
Description
Colorless, clear solution.
Colorless, clear solution.
Description
Colorless, clear solution.
Release form
Nasal Spray 0.1%.
Pharmacological action of
Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenomimetic activity, causes narrowing of the blood vessels of the nasal mucosa, eliminating swelling and hyperemia of the nasal mucosa, restores nasal passage, facilitates.
The action of the drug occurs 5-10 minutes after its use and lasts up to 12 hours.
Indications
acute respiratory diseases with rhinitis (runny nose) symptoms
acute allergic rhinitis
pollinosis
sinusitis
eustachitis
middle otitis media (to reduce nasal mucosa a rhinitis (runny nose), acute allergic rhinitis, hay fever, sinusitis, eustachitis, otitis media (to reduce swelling of the nasopharynx), to facilitate rhinoscopy and other their diagnostic manipulations in the nasal passages.
Special instructions
Seawater, which is part of the preparation, helps to maintain the normal physiological state of the nasal mucosa due to the ability to improve the function of the ciliated epithelium and normalize the production of mucus in the goblet cells of the mucous membrane.
Not recommended for continuous use for more than 7 days. Do not exceed recommended doses, especially in children and the elderly.
Prolonged (more than 7 days) use or overdose of xylometazoline may cause a weakening of the therapeutic effect of the drug, and also increases the risk of reactive hyperemia and atrophy of the nasal mucosa.
Composition
1 ml nasal spray contains:
active substance - xylometazoline hydrochloride 0.5 mg or 1.0 mg srdlp nutrients - sea water - 250.0 mg,
potassium dihydrogen phosphate - 0.45 mg,
purified water - 754.35 mg or 753.85 mg.
Theoretical total weight - 1005.3 mg.
Dosage and Administration
Intranasally. Snoop® nasal spray 0.05% For children from 2 to 6 years old by 1 injection into each nostril (if necessary, repeat), up to three times a day.
Adults and children from 6 years of age, 2 injections in each nostril, up to three times a day. Snoop® Nasal Spray 0.1% For adults and children from 6 years old, 1 injection into each nostril (if necessary, repeat), up to three times a day. Snoop® Nasal Spray 0.1% should not be used in children under 6 years of age. The drug should not be used more often 3 times a day, the duration of the course is not more than 7 days. Before use, it is necessary to clean the nasal passages.
Remove the protective cap. Before the first use, press the bezel of the spray nozzle several times until a uniform cloud of “fog” appears. The bottle with the drug is ready for further use. When applying, insert the nozzle into the nasal cavity and press once on the rim. Keep the bottle upright.
Do not spray horizontally or down. Immediately after the injection, a light nose inhalation is recommended. After use, close the vial with a protective cap. Each vial must be used individually. After completion of therapy, the drug can be re-prescribed only after a few days.
Consult a physician regarding the duration of use in children. In case of chronic rhinitis, Snoop® 0.05% and 0.1% can only be used under medical supervision, given the risk of atrophy of the nasal mucosa. If there is no improvement after treatment, or the symptoms worsen, or new symptoms appear, you should consult your doctor.
Use the drug only according to the indications, the method of use and at the doses indicated in the instructions.
Side effects
Classification of the frequency of adverse reactions: very often (> 1/10) often (> 1/100 to <1/10) infrequently (> 1/1000 to <1/100) rarely (> 1/10 000 up to <1/1000) is very rare (<1/10000).
On the part of the immune system: Very rarely: hypersensitivity reactions (angioedema, rash, itching).
From the nervous system: Often: headache. Rarely: insomnia, depression (with prolonged use in high doses). Very rarely: restlessness, fatigue, paresthesia, hallucinations and cramps (mainly in children).
On the part of the sensory organs: Very rarely: violation of the clarity of visual perception.
From the cardiovascular system: Rarely: palpitations, increased blood pressure. Very rarely: tachycardia, arrhythmia.
From the respiratory system: Often: irritation and / or dryness of the nasal mucosa, burning, tingling, sneezing, hypersecretion of the mucous membrane of the nasopharynx. Rarely: after the use of the drug, an increase in swelling of the nasal mucosa (reactive hyperemia), nosebleed can be observed.
From the digestive system: Often: nausea. Rarely: vomiting.
Local reactions: Often: burning sensation at the site of application.
If you have side effects indicated in the instructions or are aggravated, or you notice any other side effects not listed in the instructions, notify your doctor.
Drug interaction
Simultaneous use of xylometazoline with monoamine oxidase inhibitors (MAOs), tricyclic and tetracyclic antidepressants, other local vasoconstrictors (decongestants), as well as other drugs that increase blood pressure, can lead to an increase in blood pressure, so the simultaneous use of these drugs is contraindicated.
If you are using the above or other medications (including over-the-counter), consult your doctor before using Snoop®.
overdose Symptoms:
In case of overdose, the clinical picture is an alternation of the central nervous system excitation phases (anxiety, arousal, hallucinations, convulsions) with phases of depression of the central nervous system (decrease in body temperature, sluggishness, drowsiness, coma). The following symptoms may also occur: miosis, mydriasis, increased sweating, fever, pallor, cyanosis, nausea and vomiting, tachycardia, bradycardia, cardiac arrhythmias, cardiac arrest, palpitations, increased blood pressure, decreased blood pressure, pulmonary artery pressure. , respiratory depression and apnea, psychogenic disorders.
In children, an overdose with dominant central effects with convulsions, coma and bradycardia, apnea, and an increase in blood pressure, followed by hypotension.
Treatment:
Symptomatic, under the supervision of a doctor.
If you accidentally take the drug inside - the introduction of activated carbon, gastric lavage.
In case of severe overdose, intensive care is shown in the hospital.
In serious cases, non-selective alpha-blockers can be used to lower blood pressure, antipyretics, intubation and artificial lung ventilation.
Storage conditions
At a temperature not exceeding 25 РC.
After opening the vial, the drug should be used within 12 months.
Keep out of the reach and sight of children.
Shelf life
6 years.
The contents of the vial are sterile, without preservatives.
Do not use after expiration date. If the medicine has expired, do not dispose of it in wastewater or on the street!
Put the medicine in the trash.
Deystvuyushtee substance
Xylometazoline
Conditions for dispensing from pharmacies
Without a prescription
dosage form
nasal spray
For
Appointment
Vasoconstrictor
Ursafarm Arzneimittel, Germany
Colorless, clear solution.
Release form
Nasal Spray 0.1%.
Pharmacological action of
Xylometazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenomimetic activity, causes narrowing of the blood vessels of the nasal mucosa, eliminating swelling and hyperemia of the nasal mucosa, restores nasal passage, facilitates.
The action of the drug occurs 5-10 minutes after its use and lasts up to 12 hours.
Indications
acute respiratory diseases with rhinitis (runny nose) symptoms
acute allergic rhinitis
pollinosis
sinusitis
eustachitis
middle otitis media (to reduce nasal mucosa a rhinitis (runny nose), acute allergic rhinitis, hay fever, sinusitis, eustachitis, otitis media (to reduce swelling of the nasopharynx), to facilitate rhinoscopy and other their diagnostic manipulations in the nasal passages.
Special instructions
Seawater, which is part of the preparation, helps to maintain the normal physiological state of the nasal mucosa due to the ability to improve the function of the ciliated epithelium and normalize the production of mucus in the goblet cells of the mucous membrane.
Not recommended for continuous use for more than 7 days. Do not exceed recommended doses, especially in children and the elderly.
Prolonged (more than 7 days) use or overdose of xylometazoline may cause a weakening of the therapeutic effect of the drug, and also increases the risk of reactive hyperemia and atrophy of the nasal mucosa.
Composition
1 ml nasal spray contains:
active substance - xylometazoline hydrochloride 0.5 mg or 1.0 mg srdlp nutrients - sea water - 250.0 mg,
potassium dihydrogen phosphate - 0.45 mg,
purified water - 754.35 mg or 753.85 mg.
Theoretical total weight - 1005.3 mg.
Dosage and Administration
Intranasally. Snoop® nasal spray 0.05% For children from 2 to 6 years old by 1 injection into each nostril (if necessary, repeat), up to three times a day.
Adults and children from 6 years of age, 2 injections in each nostril, up to three times a day. Snoop® Nasal Spray 0.1% For adults and children from 6 years old, 1 injection into each nostril (if necessary, repeat), up to three times a day. Snoop® Nasal Spray 0.1% should not be used in children under 6 years of age. The drug should not be used more often 3 times a day, the duration of the course is not more than 7 days. Before use, it is necessary to clean the nasal passages.
Remove the protective cap. Before the first use, press the bezel of the spray nozzle several times until a uniform cloud of “fog” appears. The bottle with the drug is ready for further use. When applying, insert the nozzle into the nasal cavity and press once on the rim. Keep the bottle upright.
Do not spray horizontally or down. Immediately after the injection, a light nose inhalation is recommended. After use, close the vial with a protective cap. Each vial must be used individually. After completion of therapy, the drug can be re-prescribed only after a few days.
Consult a physician regarding the duration of use in children. In case of chronic rhinitis, Snoop® 0.05% and 0.1% can only be used under medical supervision, given the risk of atrophy of the nasal mucosa. If there is no improvement after treatment, or the symptoms worsen, or new symptoms appear, you should consult your doctor.
Use the drug only according to the indications, the method of use and at the doses indicated in the instructions.
Side effects
Classification of the frequency of adverse reactions: very often (> 1/10) often (> 1/100 to <1/10) infrequently (> 1/1000 to <1/100) rarely (> 1/10 000 up to <1/1000) is very rare (<1/10000).
On the part of the immune system: Very rarely: hypersensitivity reactions (angioedema, rash, itching).
From the nervous system: Often: headache. Rarely: insomnia, depression (with prolonged use in high doses). Very rarely: restlessness, fatigue, paresthesia, hallucinations and cramps (mainly in children).
On the part of the sensory organs: Very rarely: violation of the clarity of visual perception.
From the cardiovascular system: Rarely: palpitations, increased blood pressure. Very rarely: tachycardia, arrhythmia.
From the respiratory system: Often: irritation and / or dryness of the nasal mucosa, burning, tingling, sneezing, hypersecretion of the mucous membrane of the nasopharynx. Rarely: after the use of the drug, an increase in swelling of the nasal mucosa (reactive hyperemia), nosebleed can be observed.
From the digestive system: Often: nausea. Rarely: vomiting.
Local reactions: Often: burning sensation at the site of application.
If you have side effects indicated in the instructions or are aggravated, or you notice any other side effects not listed in the instructions, notify your doctor.
Drug interaction
Simultaneous use of xylometazoline with monoamine oxidase inhibitors (MAOs), tricyclic and tetracyclic antidepressants, other local vasoconstrictors (decongestants), as well as other drugs that increase blood pressure, can lead to an increase in blood pressure, so the simultaneous use of these drugs is contraindicated.
If you are using the above or other medications (including over-the-counter), consult your doctor before using Snoop®.
overdose Symptoms:
In case of overdose, the clinical picture is an alternation of the central nervous system excitation phases (anxiety, arousal, hallucinations, convulsions) with phases of depression of the central nervous system (decrease in body temperature, sluggishness, drowsiness, coma). The following symptoms may also occur: miosis, mydriasis, increased sweating, fever, pallor, cyanosis, nausea and vomiting, tachycardia, bradycardia, cardiac arrhythmias, cardiac arrest, palpitations, increased blood pressure, decreased blood pressure, pulmonary artery pressure. , respiratory depression and apnea, psychogenic disorders.
In children, an overdose with dominant central effects with convulsions, coma and bradycardia, apnea, and an increase in blood pressure, followed by hypotension.
Treatment:
Symptomatic, under the supervision of a doctor.
If you accidentally take the drug inside - the introduction of activated carbon, gastric lavage.
In case of severe overdose, intensive care is shown in the hospital.
In serious cases, non-selective alpha-blockers can be used to lower blood pressure, antipyretics, intubation and artificial lung ventilation.
Storage conditions
At a temperature not exceeding 25 РC.
After opening the vial, the drug should be used within 12 months.
Keep out of the reach and sight of children.
Shelf life
6 years.
The contents of the vial are sterile, without preservatives.
Do not use after expiration date. If the medicine has expired, do not dispose of it in wastewater or on the street!
Put the medicine in the trash.
Deystvuyushtee substance
Xylometazoline
Conditions for dispensing from pharmacies
Without a prescription
dosage form
nasal spray
For
Appointment
Vasoconstrictor
Ursafarm Arzneimittel, Germany
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review